The Framework

The WIDES Approach

A structured, evidence-informed framework for the assessment and management of dry eye disease, connecting diagnosis to treatment through clinical logic.

01
Define the disease profile

Dry eye disease must first be characterized according to its dominant clinical profile rather than approached as a uniform symptomatic entity.

02
Identify the main drivers

A structured evaluation identifies the predominant mechanisms: evaporative, aqueous deficient, inflammatory, obstructive, neurogenic, or mixed.

03
Select the relevant combinations

Diagnostic tools and treatment modalities are positioned according to their clinical utility, as components of an integrated strategy.

04
Reassess and refine

Because dry eye disease is dynamic, longitudinal follow-up and therapeutic adjustment remain essential components of effective care.

Learn more 8+ Treatment Modalities 3 Diagnostic Pillars
Defining the disease profile Identifying diagnostic mechanisms Selecting treatment combinations Reassessing and refining care
01 Define the disease profile
WIDES does not promote a collection of technologies. It promotes a clinical framework designed to structure the diagnosis and management of dry eye disease in a more coherent and meaningful way.
WIDES WIDES

Treatment Modalities

Eight complementary approaches, positioned by mechanism rather than by device.

01

Intense Pulsed Light

Polychromatic light targeting periocular vessels, reducing inflammation and restoring meibomian gland function.

02

Quantum Molecular Resonance

Alternating electrical frequencies stimulating cellular activity without raising tissue temperature.

03

Jett Plasma

Controlled electroporation modulating membrane permeability to reduce lid margin inflammation.

04

Radiofrequency

High-frequency current generating endogenous heat to reactivate meibomian glands.

05

Thermotherapies

Controlled eyelid heating to liquefy inspissated meibum and facilitate gland expression.

06

Photobiomodulation

Red and near-infrared light enhancing mitochondrial function and reducing inflammation.

07

BlephEx

Mechanical lid-margin debridement removing biofilm and bacterial debris.

08

Lubricants

Targeted tear supplementation addressing aqueous, lipid, or mucin layer deficiency.

The eTAO Score

A structured scoring system integrating four clinical axes into a unified severity metric, guiding treatment selection and clinical decision-making.

eTAO Severity Score

The eTAO score integrates four clinical axes into a unified severity metric: corneal epithelium status, telangiectasia severity, meibomian gland atrophy, and gland obstruction. Each axis is graded 1 to 4, producing a composite profile that guides therapeutic decisions.

eTAO radar diagram showing four clinical axes
e : Corneal Epithelium
T : Telangiectasias
A : MG Atrophy
O : MG Obstruction
Learn About eTAO
0
No Dry Eye

Normal tear film, no structural changes, no symptoms.

1
Mild Dry Eye

Intermittent symptoms, early tear instability. Environmental triggers.

2
Moderate Dry Eye

Persistent symptoms, meibomian gland dysfunction, reduced TBUT.

3
Severe Dry Eye

Significant corneal involvement, marked inflammation, gland atrophy.

4
Very Severe Dry Eye

Refractory disease, advanced gland loss, multi-modal therapy required.

Clinical Resources

For Ophthalmologists

Access the complete WIDES framework: diagnostic protocols, treatment algorithms, and the eTAO severity scoring system. Clinical tools designed for specialists managing ocular surface disease.

Explore Clinical Resources

An international platform for Interventional Dry Eye

WIDES provides a structured environment for education, research collaboration, and the development of clinical standards in ocular surface disease.

Towards a more structured standard of dry eye care

WIDES exists to bridge the gap between emerging science and everyday clinical practice. Whether you are a seasoned specialist or just beginning to explore interventional dry eye, we provide the framework, the tools, and the community to support your journey.